- Chugai gets exclusive development and commercializing rights for AT-527 in Japan
- Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
- AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21
Click here to read full press release/ article | Ref: Chugai | Image: Wikipedia
The post Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan first appeared on PharmaShots.